Clinical trial

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-02-24

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2021-02-24Date precision: day

Registry last updated2026-03-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

KRAS G12C Mutant Solid Tumorsunresolved

Carcinoma, Non-Small-Cell Lungunresolved

Carcinoma, Colorectalunresolved

Cancer of Lungunresolved

Cancer of the Lungunresolved

Lung Cancerunresolved

Neoplasms, Lungunresolved

Neoplasms, Pulmonaryunresolved

Pulmonary Cancerunresolved

Pulmonary Neoplasmsunresolved

Interventions

tislelizumabBIOLOGICAL

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

BostonMassachusetts, United States2 SingaporeSingapore2 HoustonTexas, United States1 AtlantaGeorgia, United States1 SeoulSouth Korea1 MadridSpain1 BarcelonaSpain1 PittsburghPennsylvania, United States1 MontrealQuebec, Canada1 TaipeiTaiwan1 GuangzhouGuangdong, China1 BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04699188 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.